Secondary hyperparathyroidism: Causes and clinical implications.

Trac Comani*

Department of Biochemistry, University of Florida, Australia

Introduction

Secondary hyperparathyroidism is a condition where the parathyroid glands produce excess Parathyroid Hormone (PTH) in response to low calcium levels or other underlying health issues. Unlike primary hyperparathyroidism, which arises from problems within the parathyroid glands themselves, secondary hyperparathyroidism is a compensatory reaction to systemic conditions that disrupt calcium homeostasis. Understanding the causes and clinical implications of secondary hyperparathyroidism is crucial for diagnosing and managing this complex condition effectively. The most common cause of secondary hyperparathyroidism is Chronic Kidney Disease (CKD). In CKD, the kidneys are unable to adequately filter waste products and regulate electrolytes, leading to imbalances in calcium and phosphate levels. One of the key functions of the kidneys is to convert vitamin D into its active form, calcitriol, which is essential for proper calcium absorption in the intestines [1, 2].

In CKD, this conversion process is impaired, resulting in reduced calcium absorption and subsequently low serum calcium levels. The low calcium levels trigger the parathyroid glands to secrete more PTH in an attempt to normalize calcium levels, leading to secondary hyperparathyroidism. Another common cause of secondary hyperparathyroidism is vitamin D deficiency. Vitamin D is crucial for calcium absorption from the diet, and its deficiency can lead to inadequate calcium levels in the blood. When calcium levels drop, the parathyroid glands increase PTH production to mobilize calcium from the bones and enhance calcium reabsorption in the kidneys. Chronic vitamin D deficiency can result in prolonged elevated PTH levels, contributing to bone resorption and bone health issues. This condition can be particularly prevalent in individuals with limited sun exposure or those with dietary insufficiencies [3, 4].

Secondary hyperparathyroidism can also be associated with malabsorption conditions such as celiac disease or Inflammatory Bowel Disease (IBD). In these conditions, the absorption of nutrients, including calcium and vitamin D, is impaired, leading to deficiencies that trigger increased PTH production. The body's response involves increasing PTH levels to maintain calcium balance, but this compensatory mechanism can lead to bone demineralization and other complications over time. The clinical implications of secondary hyperparathyroidism are significant and multifaceted. One of the primary concerns is its impact on bone health. Elevated PTH levels stimulate bone resorption, a process where bone tissue is broken down to release calcium into the bloodstream. While this compensatory mechanism helps to increase blood calcium levels, it also leads to a decrease in bone density [5, 6].

Over time, this can result in conditions such as osteopenia or osteoporosis, characterized by weakened bones that are more susceptible to fractures. Patients with secondary hyperparathyroidism may experience bone pain, increased fracture risk, and other related symptoms. In addition to bone health issues, secondary hyperparathyroidism can contribute to other systemic complications. For example, elevated PTH levels can exacerbate renal complications in patients with chronic kidney disease. The increased bone turnover associated with secondary hyperparathyroidism can lead to the development of bone lesions, calcifications, and even cardiovascular problems. Vascular calcification, where calcium deposits accumulate in blood vessels, is a known complication of secondary hyperparathyroidism and can contribute to cardiovascular disease [7, 8].

Managing secondary hyperparathyroidism involves addressing the underlying causes and mitigating the effects of elevated PTH levels. For patients with chronic kidney disease, treatment focuses on managing kidney function and balancing calcium and phosphate levels. This often involves the use of phosphate binders to reduce phosphate levels, active vitamin D analogs to improve calcium absorption, and sometimes calcimimetics to reduce PTH secretion. Regular monitoring of kidney function, calcium, phosphate, and PTH levels is crucial to adjust treatment and prevent complications [9, 10].

Conclusion

In summary, secondary hyperparathyroidism is a condition characterized by excessive PTH production due to underlying health issues that disrupt calcium balance. Common causes include chronic kidney disease, vitamin D deficiency, and malabsorption conditions. The clinical implications of secondary hyperparathyroidism are significant, with potential impacts on bone health, cardiovascular function, and overall well-being. Effective management requires a comprehensive approach that addresses the underlying causes, such as improving kidney function, supplementing vitamin D and calcium, and managing malabsorption disorders. By understanding and addressing the multifaceted nature of

***Correspondence to:** Trac Comani, Department of Biochemistry, University of Florida, Australia. E-mail: tracom@uf.au

***Received:** 29-Jul-2024, Manuscript No. AAAGIM-24-145865; **Editor assigned:** 01-Aug-2024, PreQC No. AAAGIM-24-145865 (PQ); **Reviewed:** 16-Aug-2024, QC No. AAAGIM-24-145865; **Revised:** 19-Aug-2024, Manuscript No. AAAGIM-24-145865(R); **Published:** 26-Aug-2024, DOI: 10.35841/aaagim-8.4.248*

***Citation:** Comani T. Secondary hyperparathyroidism: Causes and clinical implications. Arch Gen Intern Med. 2024;8(4):248.*

secondary hyperparathyroidism, healthcare providers can better support patients in achieving optimal health and preventing complications associated with this condition.

References

1. Hiramitsu T, Hasegawa Y, Futamura K, et al. Treatment for secondary hyperparathyroidism focusing on parathyroidectomy. Front Endocrinol. 2023;14:1169793.
2. Strebeck RJ, Schneider AM, Whitcombe DD, et al. Hyperparathyroidism in pregnancy: a review of the literature. Obstet Gynecol Surv. 2022;77(1):35-44.
3. Kim SJ, Shoback DM. Sporadic primary hyperparathyroidism. Endocrinol Metab Clin North Am. 2021;50(4):609-28.
4. Almquist M, Isaksson E, Clyne N. The treatment of renal hyperparathyroidism. Endocr Relat Cancer. 2020;27(1):R21-34.
5. Slattery L, Hunt JP. Contemporary management of primary hyperparathyroidism. Surg Clin North Am. 2022;102(2):251-65.
6. Jamal SA, Miller PD. Secondary and tertiary hyperparathyroidism. J Clin Densitom. 2013;16(1):64-8.
7. Lau WL, Obi Y, Kalantar-Zadeh K. Parathyroidectomy in the management of secondary hyperparathyroidism. Clin J Am Soc Nephrol. 2018;13(6):952-61.
8. Messa P, Alfieri CM. Secondary and tertiary hyperparathyroidism. Front Horm Res. 2019;51:91-108.
9. Mizobuchi M, Ogata H, Koiwa F. Secondary hyperparathyroidism: pathogenesis and latest treatment. Ther Apher Dial. 2019;23(4):309-18.
10. Rodríguez-Ortiz ME, Rodríguez M. Recent advances in understanding and managing secondary hyperparathyroidism in chronic kidney disease. F1000Res. 2020;9.

Citation: *Comani T. Secondary hyperparathyroidism: Causes and clinical implications. Arch Gen Intern Med. 2024;8(4):248.*